A gene panel is a collection of genes, associated with a particular disease or phenotype, that have been grouped together to enable their simultaneous testing. Gene panels can contain anything from two to thousands of genes, allowing clinicians to move beyond single-gene testing, supporting faster, more precise patient management.
Panels We Offer
At Source Genomics, we currently offer a range of gene panels across hereditary cancer, which provide comprehensive analysis of inherited cancer risk, as well as targeted multigene panels to help guide targeted therapy use.
Our Hereditary Cancer Gene Panels
Hereditary Cancer Panel
- Disease Targeted: Hereditary Cancer
- Who is the test for: Patients with family history, clinical suspicion or diagnosis of cancer.
- Test Approach: Next generation Sequencing (NGS)
- No. of Genes: 31
- Panel Content: APC, ATM1, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK22, EPCAM3, HOXB13, MLH1, MSH2, MSH6, MUTYH, NF1, NTHL1, PALB2, PMS24, POLD1, POLE, PTEN, RAD51C, RAD51D, SMAD4, STK11, TP53, VHL
- Turn around time: 3 weeks / 15 working days
- Specimen requirements: Saliva
Hereditary cancer is caused by an inherited genetic variant passed down through families, which increases the risk of developing certain cancers, typically accounting for 5-10% of most cancer cases. Common hereditary cancers include breast, ovarian, and colorectal cancer. Hereditary cancers are often linked to inherited variants in genes that help control cell growth and division. Well-known examples are the BRCA1/BRCA2 genes for breast and ovarian cancer, and the APC gene for Familial Adenomatous Polyposis (FAP) of the colon.
Hereditary Breast Cancer Panel
- Disease Targeted: Hereditary Breast Cancer
- Who is the test for: Patients with family history, clinical suspicion or diagnosis of breast cancer.
- Test Approach: Next generation Sequencing (NGS)
- No. of Genes: 9
- Panel Content: ATM1, BARD1, BRCA1, BRCA2, CHEK22, PALB2, PTEN, STK11, TP53
- Turn around time: 3-4 weeks / 15-20 working days
- Specimen requirements: Saliva
Around 5–10% of all breast cancers are caused by inherited genetic variants passed down through families. These variants affect genes involved in DNA repair and cell growth regulation, most notably BRCA1, BRCA2, PALB2, TP53, and others included in this panel.
Individuals who inherit a pathogenic variant in one of these genes have a significantly increased lifetime risk of breast cancer, often at a younger age and sometimes with a more aggressive subtype (such as triple-negative breast cancer in BRCA1 carriers). For example, BRCA1/2 variants can increase lifetime breast cancer risk to 60–80%, and may also increase the risk of ovarian and other cancers.
Hereditary Breast and Gynecological Cancer Panel
- Disease Targeted: Hereditary Breast and Gynaecological Cancer
- Who is the test for: Patients with family history, clinical suspicion or diagnosis of breast and gynaecological cancer.
- Test Approach: Next generation Sequencing (NGS)
- No. of Genes: 9
- Panel Content: ATM1, BARD1, BRCA1, BRCA2, BRIP1, CHEK22, EPCAM3, MLH1, MSH2, MSH6
- Turn around time: 3-4 weeks / 15-20 working days
- Specimen requirements: Saliva
Hereditary Breast and Gynaecological Cancer refers to breast, ovarian, and related cancers that arise due to inherited genetic variants. These variants can substantially increase an individual’s lifetime cancer risk and can be passed from one generation to the next.
Breast cancer is one of the most common cancers in women, and 5–10% of cases are hereditary. The highest-risk genes are BRCA1 and BRCA2, though other genes such as PALB2, TP53, CHEK2, and BARD1 also play important roles. Pathogenic variants in BRCA1/2 occur in approximately 1 in 100–200 people in the general population.
Many gynaecological cancers also have a strong genetic component. Ovarian cancer is commonly associated with BRCA1/2 variants and is often part of hereditary breast–ovarian cancer syndromes. Endometrial cancer can be linked to inherited variants in the Lynch syndrome genes — including MLH1, MSH2, MSH6, and PMS2.
Hereditary Cancer BRCA Testing
- Disease Targeted: Cancer
- Who is the test for: Patients with family history, clinical suspicion or diagnosis of cancer.
- Test Approach: Next generation Sequencing (NGS)
- No. of Genes: 2
- Panel Content: BRCA1, BRCA2
- Turn around time: 3-4 weeks / 15-20 working days
- Specimen requirements: Saliva
BRCA1 and BRCA2 are genes that play a crucial role in repairing DNA damage. When a person inherits a pathogenic variant in either gene, their ability to repair DNA is reduced, leading to a significantly higher lifetime risk of several cancers. BRCA testing identifies these inherited variants and is one of the most important tools in hereditary cancer risk assessment, particularly for breast, ovarian, prostate, and pancreatic cancers.
Pathogenic variants in BRCA1/2 are relatively common, occurring in around 1 in 100–200 people, and can increase cancer risk substantially. For example, BRCA carriers face up to a 60–80% lifetime risk of breast cancer and a significantly increased risk of ovarian cancer (particularly BRCA1). In men, BRCA2 variants raise the risk of both prostate cancer and male breast cancer.
Hereditary Lung Cancer Panel
- Disease Targeted: Non-Small Cell Lung Cancer
- Who is the test for: Patients with family history, clinical suspicion or diagnosis of Lung cancer.
- Test Approach: Next generation Sequencing (NGS)
- No. of Genes: 30
- Panel Content: DNA TARGETS: AKT1, BRAF, EGFR, ERBB2, FOXL2, GNA11, GNAQ, GNAS, HRAS, IDH1, IDH2, KIT, KRAS, MET, NRAS, PDGFRA, PIK3CA, RET, TERT, TP53, ALK, APC, AR, ATRX, CDK4, CDK6, CDKN2A, CTNNB1, DDR2, ERBB3, ERBB4, ESR1, FBXW7, FGFR1, FGFR2, FGFR3, H3F3A, HISTH3B, JAK2, MAP2K1, MAP2K2, MTOR, MYC, NOTCH1, NOTCH2, NOTCH3, NOTCH4, NTRK1, NTRK2, NTRK3, POLD1, POLE, PTEN, RAF1, RB1, RICTOR, ROS1, SMAD4, SMO, VHL, KEAP1, STK11
RNA FUSIONS: ALK, RET, ROS1, MET Exon 14 Skipping - Turn around time: 7-10 days
- Specimen requirements: Saliva
Hereditary lung cancer refers to lung cancer that develops due to inherited genetic variants that increase an individual’s susceptibility to the disease. Although lung cancer is primarily driven by environmental exposures, most notably smoking, air pollution, and occupational carcinogens, a small percentage of cases arise from inherited predispositions.
These inherited variants can influence how cells grow, divide, and repair DNA damage, or how the body responds to environmental toxins.
Hereditary Melanoma and Skin Cancer Panel
- Disease Targeted: Hereditary Melanoma and Skin Cancer Panel
- Who is the test for: Patients with family history, clinical suspicion or diagnosis of Hereditary Melanoma and skin cancer.
- Test Approach: Next generation Sequencing (NGS)
- No. of Genes: 5
- Panel Content: DNA TARGETS: BAP1, BRCA2, CDK4, CDKN2A, PTEN
- Turn around time: 3-4 weeks / 15-20 working days
- Specimen requirements: Saliva
Hereditary melanoma refers to melanoma that arises due to inherited genetic variants that significantly increase a person’s susceptibility to developing skin cancer. While most melanoma cases are caused by environmental factors, especially ultraviolet (UV) exposure, a small proportion (around 5–10%) are linked to hereditary predisposition.
Hereditary Prostate Cancer Panel
- Disease Targeted: Hereditary Prostate Cancer Panel
- Who is the test for: Patients with family history, clinical suspicion or diagnosis of Hereditary Melanoma and skin cancer.
- Test Approach: Next generation Sequencing (NGS)
- No. of Genes: 9
- Panel Content: ATM1, BRCA1, BRCA2, CHEK2, EPCAM3, HOXB13, MLH1, MSH2, MSH6
- Turn around time: 3-4 weeks / 15-20 working days
- Specimen requirements: Saliva
Around 5–10% of all prostate cancers are caused by inherited genetic variants passed down through families. The most clinically important of these are faults in genes responsible for repairing DNA, particularly BRCA1, BRCA2, ATM, CHEK2, and the mismatch repair genes (MLH1, MSH2, MSH6).
Men who inherit a pathogenic variant in one of these genes have a significantly higher lifetime risk of developing prostate cancer, often at a younger age and sometimes with a more aggressive disease course. BRCA2 is especially relevant: men with a BRCA2 variant have a 2–6 times higher risk of prostate cancer and may benefit from earlier detection, closer monitoring, or specific targeted treatments if cancer develops.
MSI Testing
- Disease Targeted: Lynch Syndrome
- Who is the test for: Patients with family history, clinical suspicion or diagnosis of Lynch syndrome.
- Test Approach: Next generation Sequencing (NGS)
- No. of Genes: 1
- Panel Content:Â MSI
- Turn around time: 3-4 weeks / 15-20 working days
- Specimen requirements: Saliva
Clinical Value of Hereditary Cancer Testing
Early and personalised screening
Individuals with high-risk variants (e.g., BRCA1/2, Lynch syndrome genes) can begin enhanced surveillance programmes, improving early detection and outcomes.
Targeted risk reduction strategies
Results may guide preventative measures such as risk-reducing surgery.
Treatment decision making
In patients with cancer, germline findings may influence therapy selection, for example, BRCA1/2 carriers may benefit from PARP inhibitors or specific chemotherapies.
Family cascade testing
Relatives can be tested for the same variant, allowing proactive management for those who carry it and reassurance for those who do not.
Partnering with Us
Integrating hereditary cancer testing and comprehensive tumour profiling into your practice is seamless with our support. Whether you are a pathologist enhancing your diagnostic toolkit or a clinician seeking deeper molecular insights for your patients, we are here to guide you through every stage.
Contact us to explore how our cancer panel testing can be customised to your clinical workflow. Together, we can advance precision oncology, refine treatment selection, and deliver more confident, personalised care for every patient.